DT interview 11th Feb, page-31

Other manufacturing locations are not mentioned, no outsourced licencing as previously hinted at, one of the reasons of my buy sentiment as mentioned a while ago.
We are producing at Operon, which has limited capacity.

While everything looks positive for regulatory approvals and rollout of the test, the numbers are not convincing to justify market cap.
Price got ahead of itself, as it is so often the case prior to commercialisation numbers.

Ellume, at this stage, had already 70 mil investment from International partners.
We have none.
They produced very quickly a 300 mil contract with the US for 200 mil tests while we have not heard back from the Israelis, the Americans, the Chinese.
We have maximum 8 miltests annually, provided Operon dumps all other tests they produce, which is unlikely and if they expand from current 4 mil tests.


While I support the enthusiasm on this thread, I do find it lacking in research about the
actual numbers and revenue drivers.
Derek mentioned that additional jurisdictions would need additional regulatory approvals, which will take more time.
Currently we produce in Spain at small capacity, if all goes well, which I believe.


There is the clear danger of a wake up call when numbers and orders are published that
the sky high expectations of many will receive a reality check.
Having said that, I do believe that our brand will expand, but at a pace much slower than market cap advances in recent times.
Operon numbers are long priced in plus plenty of speculation, which is risky.


Current MC is sustainable when additional manufacturing capabilities are announced, outsourced licencing achieved and battery news forthcoming out of their incredibly long silence.

all IMO